SC
RXRX icon

Steven Cohen’s Recursion Pharmaceuticals RXRX Stock Holding History

Steven Cohen’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,300
Closed -$142K – 4507
2026
Q1 		$142K Buy
+46,300
New +$179K ﹤0.01% 3575

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Steven Cohen's RXRX Position: Q1 2026 in Review

Steven Cohen sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 654,211 shares — an estimated $2.53M sold.

Steven Cohen first reported a position in RXRX in Q3 2023 and held it in 4 quarters. The position peaked at $14.5M in Q4 2023. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Steven Cohen reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 654,211 Recursion Pharmaceuticals shares in Q1 2026, an estimated $2.53M.
  • Steven Cohen first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Steven Cohen's Recursion Pharmaceuticals position peaked at $14.5M in Q4 2023.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.